Bacterial Infection

| CRISPR Medicine | This is an overview of clinical trials of antibacterial therapies

Clinical Update: SNIPR Biome Doses First Human...

Apr. 20, 2022

SNIPR BIOME, Denmark, announced today that it has dosed the first human subjects in its Phase 1 clinical trial for SNIPR001, an orally administered...

CRISPR IND Updates: E. coli, Beta Thalassemia, and...

Jan. 12, 2022

In our first clinical update of 2022, we look at three new IND approvals for gene-edited therapies for life-threatening E. coli infections,...

CRISPR Medicine in 2021 – What a Phenomenal Year...

Dec. 28, 2021

In 2021, we've seen positive clinical data for the first ever in vivo CRISPR medicines, base editors are heading for the clinic, and CRISPR therapies...

First CRISPR Manipulation of a Mammalian...

Nov. 29, 2021

Researchers use the M13 bacteriophage to deliver a CRISPR-Cas9 system to Escherichia coli in the mouse gut. The approach marks the first-ever use of...

CMN Webinar Catch Up: CRISPR Delivery Systems

Jun. 9, 2021

Two weeks ago, we hosted a CMN webinar on CRISPR Delivery Systems. Several hundred attendees from all continents tuned in for the live event. Here's a...